No, Zofran (ondansetron) should NOT be given to a 5-month-old infant for vomiting
The current evidence does not support ondansetron use in infants younger than 6 months of age. The most relevant clinical guidelines and FDA labeling consistently specify age cutoffs that exclude your 5-month-old patient.
Age-Specific Restrictions from Guidelines
The 2017 IDSA guidelines for infectious diarrhea explicitly state that ondansetron may be given to facilitate oral rehydration only in children >4 years of age and adolescents with acute gastroenteritis 1. This is a weak recommendation with moderate evidence quality, but importantly, it excludes infants entirely.
Even in the specialized context of food protein-induced enterocolitis syndrome (FPIES), where ondansetron is considered for severe allergic reactions, the 2017 international consensus guidelines specify ondansetron use only if age 6 months and older 2. These guidelines consistently state "If age 6 mo and older: consider/administer ondansetron" across all severity levels of FPIES episodes.
FDA Labeling Does Not Address Infants
The FDA-approved ondansetron labeling provides dosing for pediatric patients starting at 4 years of age for chemotherapy-induced nausea/vomiting 3. The label explicitly states "there is no experience with the use of ondansetron orally disintegrating tablets in the prevention of postoperative nausea and vomiting in pediatric patients" and provides no guidance for infants 3.
What the Research Shows
While research studies have evaluated ondansetron in pediatric gastroenteritis, the evidence base is limited for very young infants:
- A 2010 RCT included children as young as 5 months, showing reduced vomiting 4, but this single study is insufficient to override guideline recommendations
- Most systematic reviews and meta-analyses focus on broader pediatric populations without specific safety data for infants under 6 months 5, 6
- A 2016 study included children from 3 months but used alternate-day design rather than true randomization 7
The critical issue is that safety and efficacy data in infants <6 months remain sparse, and no major guideline endorses use in this age group.
What You Should Do Instead
For a 5-month-old with vomiting:
- Prioritize oral rehydration therapy - This is the cornerstone of management for all ages and has strong evidence 1
- Continue breastfeeding if applicable - Human milk feeding should continue throughout the illness 8, 1
- Consider IV rehydration if the infant shows signs of moderate-to-severe dehydration, altered mental status, or failure of oral rehydration 1
- Evaluate for serious underlying causes - In a 5-month-old, bilious vomiting or persistent forceful vomiting warrants imaging to rule out malrotation, pyloric stenosis, or other anatomic abnormalities 9
Common Pitfalls to Avoid
- Do not extrapolate pediatric data to infants - The 4-year age cutoff in IDSA guidelines exists because younger children lack adequate safety data
- Do not use ondansetron as a substitute for rehydration - Even when appropriate, antiemetics are adjunctive therapy only 1, 8, 1
- Be aware of cardiac concerns - Ondansetron can prolong the QT interval, a particular concern in infants with undiagnosed cardiac conditions 2
In summary, wait until the infant is at least 6 months old before considering ondansetron, and even then, focus on oral rehydration as first-line therapy. For a 5-month-old with concerning vomiting, pursue appropriate diagnostic workup and supportive care rather than antiemetic medication.